Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma
Hareth Nahi,
Gabriel Afram,
Katarina Uttervall
et al.
Abstract:BackgroundThe presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression‐free survival (PFS) and overall survival (OS).MethodsAt our department, we recommend lenalidomide maintenance for patients who are MRD+ after ASCT, while MRD‐negative (MRD−) patients, after information about the national guidelines, were not advised to follow this regimen.ResultsOut of the total 228 patients, 175 received ASCT fo… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.